Pharmacology and Treatment
Meta-Analysis of 5% Imiquimod and 0.5% Podophyllotoxin in the Treatment of Condylomata AcuminataYan J.a, b · Chen S.-L.c · Wang H.-N.b · Wu T.-X.d
aJinan City Hospital for Skin Disease Prevention and Treatment and bSchool of Pharmacy, Shandong University, Jinan, cInstitute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, and dChinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, China
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Genital warts are a common sexually transmitted disease caused by human papillomaviruses. Podophyllotoxin 0.5%, approved for patient self-administration, has been used most extensively in the treatment of genital warts. Imiquimod, a novel immune response modifier capable of inducing interferon-α and a variety of cytokines, has been examined as a potential treatment for genital warts. But 0.5% podophyllotoxin and 5% imiquimod have not been compared in any extensive and formal studies, although they are the common topical agents for genital warts. Objective: To evaluate the efficacy and safety of topical 5% imiquimod and 0.5% podophyllotoxin in the treatment of genital warts. Methods: We searched Medline (1966 to June 2005), Embase (1974 to June 2005) and the Cochrane Controlled Trials Register (issue 3, 2005). Randomized controlled trials of 5% imiquimod or 0.5% podophyllotoxin in the treatment of genital warts were collected. Two reviewers extracted the data and independently assessed the quality of the included medical literature. Then, meta-analysis was conducted. Results: Twelve studies including 3 placebo-controlled trials of imiquimod and 9 placebo-controlled trials of podophyllotoxin were included. The clinical cure rates of imiquimod and podophyllotoxin were 50.34 and 56.41%, respectively, without statistically significant differences between the two (p > 0.05). A combined analysis of the 3 studies on imiquimod showed a statistically significant difference to the placebo group [pooled odds ratio (OR) 11.65, 95% confidence interval (CI) 6.05–22.44], as did a combined analysis of the 9 studies on podophyllotoxin (pooled OR 16.70, 95% CI 7.06–39.48). The most common adverse events of imiquimod were erythema, erosion, excoriation, itching and burning; those of podophyllotoxin were burning, pain, erosion, itching and inflammation. Conclusion: Imiquimod and podophyllotoxin possess similar curative effects on condylomata acuminata but podophyllotoxin has more serious adverse effects.
© 2006 S. Karger AG, Basel
- Gangemi JD, Pirisi L, Angell M, Kreider JW: HPV replication in experimental models: effects of interferon. Antiviral Res 1994;24:175–190.
Cates W Jr: Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex Transm Dis 1999;26(suppl 4):2–7.
Hughes G, Simms I, Rogers PA, Swan AV, Catchpole M: New cases seen at genitourinary medicine clinics: England 1997. Commun Dis Rep CDR Suppl 1998;8:1–11.
- Koutsky L: Epidemiology of genital papillomavirus infection. Am J Med 1997;102:3–8.
- Beutner KR, Ferenczy A: Therapeutic approaches to genital warts. Am J Med 1997;102:28–37.
- Ferenczy A, Mitao M, Nagai N, Silverstein SJ, Crum CP: Latent papillomavirus and recurring genital warts. N Engl J Med 1985;313:784–788.
- Czelusta AJ, Evans T, Arany I, Tyring SK: A guide to immunotherapy of genital warts: focus on interferon and imiquimod. Biodrugs 1999;11:319–332.
- Beutner KR, Spruance SL, Hougham AJ, Fox TL, Owens ML, Douglas JM Jr: Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol 1998;38:230–239.
- Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA: Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group: Human Papillomavirus. Arch Dermatol 1998;134:25–30.
- Arican O, Guneri F, Bilgic K, Karaoglu A: Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 2004;31:627–631.
- Beutner KR, Conant MA, Friedman-Kien AE, Illeman M, Artman NN, Thisted RA, King DH: Patient-applied podofilox for treatment of genital warts. Lancet 1989;8642:831–834.
- Kirby P, Dunne A, King DH, Corey L: Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. Am J Med 1990;88:465–469.
- Von Krogh G, Szpak E, Andersson M, Bergelin I: Self-treatment using 0.25–0.50% podophyllotoxin-ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med 1994;70:105–109.
- Von Krogh G, Hellberg D: Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women: a placebo-controlled, double-blind study. Sex Transm Dis 1992;19:170–174.
- Syed TA, Lundin S, Ahmad SA: Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of condylomata acuminata in women: a placebo-controlled, double-blind study. Dermatology 1994;189:142–145.
- Syed TA, Khayyami M, Kriz D, Svanberg K, Kahlon RC, Ahmad SA, Ahmad SA: Management of genital warts in women with human leukocyte interferon-alpha vs podophyllotoxin in cream: a placebo-controlled, double-blind, comparative study. J Mol Med 1995;73:255–258.
- Syed TA, Cheema KM, Khayyami M, Ahmad SA, Ahmad SH, Ahmad S, Ahmad SA: Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males: a placebo-controlled, double-blind, comparative study. Dermatology 1995;191:129–132.
- Tyring S, Edwards L, Cherry LK, Ramsdell WM, Kotner S, Greenberg MD, Vance JC, Barnum G, Dromgoole SH, Killey FP, Toter T: Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998;134:33–38.
- Greenberg MD, Rutledge LH, Reid R, Berman NR, Precop SL, Elswick RK Jr: A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol 1991;77:735–739.
- Bonnez W, Elswick RK Jr, Bailey-Farchione A, Hallahan D, Bell R, Isenberg R, Stoler MH, Reichman RC: Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med 1994;96:420–425.
Beutner K, Edwards L, Owens M, Fox T: Comparison of two vehicle-controlled trials of imiquimod 5% cream for the treatment of external genital warts (abstract 1259). J Invest Dermatol 1998;110:682.
- Ferenczy A: Immune response modifiers: imiquimod. J Obstet Gynaecol 1998;18(suppl 2):76–78.
- Sauder DN, Skinner RB, Fox TL, Owens ML: Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 2003;30:124–128.
- Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.
- Lacey CJ, Goodall RL, Tennvall GR, Maw R, Kinghorn GR, Fisk PG, Barton S, Byren I: Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 2003;79:270–275.
- Trofatter KF Jr, Ferenczy A, Fife KH: Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. Int J Gynaecol Obstet 2002;76:191–193.
- Fife KH, Ferenczy A, Douglas JM Jr, Brown DR, Smith M, Owens ML: Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. Sex Transm Dis 2001;28:226–231.
- Gollnick H, Barasso R, Jappe U, Ward K, Eul A, Carey-Yard M, Milde K: Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001;12:22–28.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.